Fmr LLC cut its position in Emergent Biosolutions, Inc. (NYSE:EBS) by 24.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 218,701 shares of the biopharmaceutical company’s stock after selling 70,129 shares during the period. Fmr LLC owned 0.53% of Emergent Biosolutions worth $7,416,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Riverhead Capital Management LLC grew its stake in shares of Emergent Biosolutions by 102.8% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 1,542 shares during the period. Creative Planning grew its stake in shares of Emergent Biosolutions by 1.2% in the 2nd quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 55 shares during the period. Laurion Capital Management LP acquired a new stake in shares of Emergent Biosolutions in the 2nd quarter valued at about $214,000. State of Alaska Department of Revenue grew its stake in shares of Emergent Biosolutions by 79.9% in the 2nd quarter. State of Alaska Department of Revenue now owns 6,871 shares of the biopharmaceutical company’s stock valued at $232,000 after buying an additional 3,051 shares during the period. Finally, Municipal Employees Retirement System of Michigan grew its stake in shares of Emergent Biosolutions by 1.7% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 10,720 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 180 shares during the period. Institutional investors own 85.67% of the company’s stock.
Several brokerages have recently commented on EBS. Zacks Investment Research upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Wednesday, October 25th. Wells Fargo & Company restated an “outperform” rating and issued a $43.00 target price (up from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. Finally, BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Emergent Biosolutions presently has an average rating of “Buy” and an average target price of $45.00.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.26 by ($0.13). Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. The company had revenue of $100.77 million during the quarter, compared to the consensus estimate of $111.57 million. During the same period in the previous year, the company earned ($0.05) earnings per share. Emergent Biosolutions’s quarterly revenue was up 10.4% on a year-over-year basis.
WARNING: “Fmr LLC Trims Stake in Emergent Biosolutions, Inc. (EBS)” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/02/fmr-llc-trims-stake-in-emergent-biosolutions-inc-ebs.html.
In other Emergent Biosolutions news, Director Ronald Richard sold 22,415 shares of the firm’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $40.00, for a total transaction of $896,600.00. Following the completion of the transaction, the director now owns 24,676 shares of the company’s stock, valued at $987,040. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Fuad El-Hibri sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $40.50, for a total transaction of $1,012,500.00. Following the transaction, the chairman now directly owns 1,555,216 shares of the company’s stock, valued at approximately $62,986,248. The disclosure for this sale can be found here. Over the last three months, insiders sold 180,227 shares of company stock valued at $6,993,970. 16.50% of the stock is owned by insiders.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.